Publication: HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine.
dc.contributor.author | Gutiérrez-Bautista, Juan Francisco | |
dc.contributor.author | Sampedro, Antonio | |
dc.contributor.author | Gómez-Vicente, Esther | |
dc.contributor.author | Rodríguez-Granger, Javier | |
dc.contributor.author | Reguera, Juan Antonio | |
dc.contributor.author | Cobo, Fernando | |
dc.contributor.author | Ruiz-Cabello, Francisco | |
dc.contributor.author | López-Nevot, Miguel Ángel | |
dc.date.accessioned | 2023-05-03T14:24:12Z | |
dc.date.available | 2023-05-03T14:24:12Z | |
dc.date.issued | 2022-03-06 | |
dc.description.abstract | The vaccines designed against the SARS-CoV-2 coronavirus are based on the spike (S) protein. Processing of the S protein by antigen-presenting cells (APC) and its subsequent presentation to T cells is an essential part of the development of a humoral response. HLA-class II alleles are considered immune response genes because their codified molecules, expressed on the surface of APCs (macrophages, dendritic, and B cells) present antigenic peptides to T cell via their T cell receptor (TCR). The HLA-class II genes are highly polymorphic, regulating what specific peptides induce follicular helper T cells (TFH) and promote B lymphocyte differentiation into plasma or memory B cells. This work hypothesizes that the presence of certain HLA-class II alleles could be associated with the intensity of the humoral response (amount, length) to the SARS-CoV2 mRNA 1273 vaccine. We have studied the relationship between the HLA-class II typing of 87 health workers and the level of antibodies produced 30 days after vaccination. We show a possible association between the HLA-DRB1* 07:01 allele and the HLA-DRB1*07:01~DQA1*02:01~DQB1*02:02 haplotype to a higher production of antibodies 30 days after the administration of the second dose of mRNA-1273. | |
dc.identifier.doi | 10.3390/vaccines10030402 | |
dc.identifier.issn | 2076-393X | |
dc.identifier.pmc | PMC8949280 | |
dc.identifier.pmid | 35335034 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949280/pdf | |
dc.identifier.unpaywallURL | https://www.mdpi.com/2076-393X/10/3/402/pdf?version=1646566147 | |
dc.identifier.uri | http://hdl.handle.net/10668/21606 | |
dc.issue.number | 3 | |
dc.journal.title | Vaccines | |
dc.journal.titleabbreviation | Vaccines (Basel) | |
dc.language.iso | en | |
dc.organization | Hospital Universitario Virgen de las Nieves | |
dc.organization | Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA) | |
dc.pubmedtype | Journal Article | |
dc.rights | Attribution 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | HLA associations | |
dc.subject | anti-S antibodies | |
dc.subject | mRNA-1273 vaccine | |
dc.title | HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 10 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1